IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes for Metastases
Study Summary
This trial is testing the effects of brain tumor-specific immune cells on patients with leptomeningeal disease from glioblastoma, ependymoma or medulloblastoma.
- Leptomeningeal Metastases
- Glioblastoma
- Medulloblastoma
- Ependymoma
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 15 Secondary · Reporting Duration: 15 years
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Treatment (IL13Ralpha2-CAR T cells)
1 of 1
Experimental Treatment
30 Total Participants · 1 Treatment Group
Primary Treatment: IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are there opportunities currently open to join this research endeavor?
"According to information found on the clinicaltrials.gov website, enrollment for this trial is still open. The study was initially posted in March 5th 2021 and has been amended as ofMarch 9th 2022." - Anonymous Online Contributor
What is the upper limit of people participating in this investigation?
"Affirmative. According to the clinicaltrials.gov website, this research initiative is actively seeking participants and was initially published on March 5th 2021; it has since been updated on March 9th 2022. The study requires 30 volunteers to be sourced from a single site." - Anonymous Online Contributor
Has the FDA approved IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes for therapeutic use?
"Due to the limited clinical data available, our team has assigned a score of 1 for the safety of IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes in this Phase 1 trial." - Anonymous Online Contributor